

RECEIVED
CENTRAL FAX CENTER

JAN 05 2005

Attorney Docket No.: 5686.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Teng et al. Confirmation No.: 8481
Serial No.: 09/483,504 Group Art Unit: 1624
Filed: January 14, 2000 Examiner: S. Patel
For: Non-Peptide GLP-1 Agonists

PETITION AND FEE FOR EXTENSION OF TIME (37 C.F.R. 1.136(a))

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

It is respectfully requested that the time for response to the Office Action dated July 6, 2004 be extended for a period of 3 months from October 6, 2004 to January 6, 2004. Applicant(s) hereby petition(s) for such extension of time.

Please charge the required fee, estimated to be \$1020, with this application and to credit any overpayments to Novo Nordisk Pharmaceuticals, Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: January 5, 2005

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650
PATENT TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

Attorney Docket No.: 5686.200-US

JAN 05 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Teng et al. Confirmation No.: 8481
Serial No.: 09/483,504 Group Art Unit: 1624
Filed: January 14, 2000 Examiner: S. Patel
For: Non-Peptide GLP-1 Agonists

PETITION AND FEE FOR EXTENSION OF TIME (37 C.F.R. 1.136(a))

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

It is respectfully requested that the time for response to the Office Action dated July 6, 2004 be extended for a period of 3 months from October 6, 2004 to January 6, 2004. Applicant(s) hereby petition(s) for such extension of time.

Please charge the required fee, estimated to be \$1020, with this application and to credit any overpayments to Novo Nordisk Pharmaceuticals, Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: January 5, 2005

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650
PATENT TRADEMARK OFFICE